Good transplant outcomes in hypertrophic cardiomyopathy

(HealthDay) -- Post-heart transplant survival does not differ significantly between patients with hypertrophic cardiomyopathy (HC) and those with other types of heart disease, according to a study published in the Aug. 15 issue of The American Journal of Cardiology.

To elucidate the post-transplant prognosis for patients with HC, Tomoko S. Kato, M.D., Ph.D., from Columbia University in New York City, and colleagues retrospectively reviewed 813 consecutive undergoing from 1999 to 2010. The clinical course was compared for 41 patients with idiopathic HC, 373 patients with ischemic heart disease, and 398 patients with other heart disease.

The researchers found that the HC patients were significantly younger than those with ischemic heart disease (47.8 ± 14.0 versus 57.1 ± 9.4 years). Compared with patients with ischemic heart disease or other heart disease, a significantly lower proportion of patients with HC underwent ventricular assist device surgery for bridge-to-transplant (14.6 percent versus 31.1 and 35.7 percent, respectively). Patients with HC had better post-transplant survival than that those with ischemic heart disease at one and five years (P = 0.0359), although survival did not differ significantly from those with other heart disease. Reduced post-transplant survival was seen for those with HC on univariate, but not multivariate, analyses. Most patients with HC had non-dilated left ventricles, and post-transplant survival was similar for those with dilated and non-dilated left ventricles.

"In conclusion, the post-transplant survival of those with HC did not differ from those of the subjects who underwent transplant for other non-HC indications," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Heart transplant patients at risk for serious skin cancers

Jun 30, 2011

A new study published in the American Journal of Transplantation reveals that there is a significant risk of serious skin cancers, including cutaneous squamous cell carcinoma and melanoma, in heart transplant patients.

Recommended for you

Supplement maker admits lying about ingredients

22 hours ago

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.